61837-66-9

Usage

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 61837-66-9 differently. You can refer to the following data:
1. A mephentoin metabolite
2. A mephytoin metabolite.

InChI:InChI=1/C11H12N2O3/c1-2-11(9(15)12-10(16)13-11)7-3-5-8(14)6-4-7/h3-6,14H,2H2,1H3,(H2,12,13,15,16)

Upstream product

• 70-70-2 4-hydroxypropiophenone 
• 506-87-6 ammonium carbonate 
• 151-50-8 potassium cyanide 

Downstream Products

• 1173022-56-4 [2H₃]3-methyl-5-ethyl-5-(4-hydroxyphenyl)hydantoin 
• 61837-65-8 (+/-)-4'-Hydroxymephenytoin 

Relevant academic research and scientific papers

Solvent effects on the absorption spectra of potentially pharmacologically active 5-alkyl-5-arylhydantoins: A structure-property relationship study

To obtain insight into the interactions of potential anticonvulsant drugs with their surrounding, two series of 5-methyl-5-aryl- and 5-ethyl-5- -arylhydantoins were synthesized and their absorption spectra were recorded in the region from 200 to 400 nm in a set of selected solvents. The effects of solvent dipolarity/polarizability and solvent-solute hydrogen bonding interactions on the absorption maxima shifts were analyzed by means of the linear solvation energy relationship (LSER) concept of Kamlet and Taft. The ratio of the contributions of specific and non-specific solvent-solute interactions were correlated with the corresponding absorption, distribution, metabolism, and excretion (ADME) properties of the studied compounds. The correlation equations were combined with different physicochemical parameters to generate new equations, which demonstrate the reasonable relationships between the solvent- solute interactions and the structure-activity parameters. Copyright (C)2013 SCS.

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

The thienopyridine derivatives ticlopidine and clopidogrel are inhibitors of ADP-induced platelet aggregation. Pharmacological activity of these prodrugs depends on cytochrome P450 (P450)-dependent oxidation to the active antithrombotic agent. In this study, we investigated the interaction potential of clopidogrel and ticlopidine by using human liver microsomes and recombinantly expressed P450 isoforms. Both clopidogrel and ticlopidine inhibited CYP2B6 with highest potency and CYP2C19 with lower potency, Clopidogrel also inhibited CYP2C9, and ticlopidine also inhibited CYP1A2, with lower potency. Inhibition of CYP2B6 was time- and concentration-dependent, and as shown by dialysis experiments, it was irreversible and dependent on NADPH, suggesting a mechanism-based mode of action. Inactivation was of nonpseudo-first-order type with maximal rates of inactivation (K inact) for clopidogrel and ticlopidine in microsomes (recombinant CYP2B6) of 0.35 (1.5 min-1) and 0.5 min-1 (0.8 min -1), respectively, and half-maximal inactivator concentrations (KI) were 0.5 μM (1.1 μM) for clopidogrel and 0.2 μM (0.8 μM) for ticlopidine. Inhibition was attenuated by the presence of alternative active site ligands but not by nucleophilic trapping agents or reactive oxygen scavengers, further supporting mechanism-based action. A chemical mechanism is discussed based on the known metabolic activation of clopidogrel and on the finding that hemoprotein integrity of recombinant CYP2B6 was not affected by irreversible inhibition. These results suggest the possibility of drug interactions between thienopyridine derivates and drug substrates of CYP2B6 and CYP2C19.

Hydantoin derivatives

New hydantoin derivatives, a process for the preparation thereof and pharmaceutical compositions containing the derivatives as active ingredients, particularly remedies for treatment of diseases caused by stress.